<?xml version="1.0" encoding="UTF-8"?>
  	<urlset xmlns="http://www.sitemaps.org/schemas/sitemap/0.9" xmlns:video="http://www.google.com/schemas/sitemap-video/1.1"><url>
        <loc>https://www.ajmc.com/view/shared-risk-factors-may-drive-cvd-mortality-in-patients-with-early-onset-crc-meng-han-tsai-phd</loc><video:video><video:publication_date>2026-05-22</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/af72d9cdef019b326804ff42e8131253333d515d-1200x640.png</video:thumbnail_loc><video:title><![CDATA[Shared Risk Factors May Drive CVD Mortality in Patients With Early-Onset CRC: Meng-Han Tsai, PhD]]></video:title><video:description><![CDATA[Young men and minority patients with early-onset CRC in urban areas face higher CVD death risk, challenging assumptions about rural disparities.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6396297459112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/expanded-label-for-efgartigimod-offers-fast-acting-treatment-for-gmg-james-f-howard-md</loc><video:video><video:publication_date>2026-05-22</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/7d78bb48c08533d14cb12f1660ea40b4335787f4-1200x640.png</video:thumbnail_loc><video:title><![CDATA[Expanded Label for Efgartigimod Offers Fast-Acting Treatment for gMG: James F. Howard, MD]]></video:title><video:description><![CDATA[James F. Howard, MD, discusses the significance of the FDA expanding the label for efgartigimod in patients with generalized myasthenia gravis (gMG).]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6396284496112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/rebuilding-vaccine-trust-amid-rising-misinformation-and-disease-resurgence-jamie-r-felzer-md-mph</loc><video:video><video:publication_date>2026-05-22</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/d025344795d409042583909adaaa6907f6721101-1200x640.png</video:thumbnail_loc><video:title><![CDATA[Rebuilding Vaccine Trust Amid Rising Misinformation and Disease Resurgence: Jamie R. Felzer, MD, MPH]]></video:title><video:description><![CDATA[Jamie R. Felzer, MD, discusses vaccine misinformation, public mistrust, and strategies to restore confidence in this science.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6396105450112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/rethinking-heterogeneity-in-community-acquired-pneumonia-care-and-outcomes-mark-metersky-md</loc><video:video><video:publication_date>2026-05-22</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/50d871380eec52c3089ec957bba5994b0807c8fd-1200x640.png</video:thumbnail_loc><video:title><![CDATA[Rethinking Heterogeneity in Community-Acquired Pneumonia Care and Outcomes: Mark Metersky, MD]]></video:title><video:description><![CDATA[Mark Metersky, MD, discussed heterogeneity, pathogens, and precision approaches in community-acquired pneumonia care.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6396104042112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/emerging-vaccine-strategies-in-pulmonary-care-at-ats-2026-jamie-r-felzer-md</loc><video:video><video:publication_date>2026-05-21</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/d025344795d409042583909adaaa6907f6721101-1200x640.png</video:thumbnail_loc><video:title><![CDATA[Emerging Vaccine Strategies in Pulmonary Care at ATS 2026: Jamie R. Felzer, MD]]></video:title><video:description><![CDATA[Jamie R. Felzer, MD, discussed emerging vaccine strategies, preventive care, and translating evolving evidence into pulmonary practice at ATS 2026.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6396106229112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/the-multiple-myeloma-revolution-happening-right-now-swarup-kumar-md</loc><video:video><video:publication_date>2026-05-21</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/3769fbed19ddd39e9b5d17a1266e0594bcbb9748-1200x640.png</video:thumbnail_loc><video:title><![CDATA[The Multiple Myeloma Revolution Happening Right Now: Swarup Kumar, MD]]></video:title><video:description><![CDATA[Swarup Kumar, MD, discusses how bispecific antibodies are pushing myeloma cure rates to 40%—and what clinicians must know about managing infections and CRS.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6396175783112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/barriers-to-ild-and-pf-care-persist-amid-diagnostic-delays-and-disparities-yet-khor-md-phd</loc><video:video><video:publication_date>2026-05-21</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/beadb17db356806dc00fb8b442361fe6e7c98d6e-1200x640.png</video:thumbnail_loc><video:title><![CDATA[Barriers to ILD and PF Care Persist Amid Diagnostic Delays and Disparities: Yet Khor, MD, PhD]]></video:title><video:description><![CDATA[Yet Khor, MD, PhD, highlights diagnostic delays, language barriers, and inequities impacting ILD and PF care access.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6396105850112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/role-of-anti-vegf-real-world-evidence-in-retinal-vascular-diseases</loc><video:video><video:publication_date>2026-05-21</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/e6a90538ee7f7775d8579cc09a8401c630648abe-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[Role of Anti-VEGF Real-World Evidence in Retinal Vascular Diseases]]></video:title><video:description><![CDATA[Real-world anti‑VEGF outcomes lag trials as durability and missed injections matter; learn how evidence guides everyday wet AMD decisions.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6396069003112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/current-role-of-anti-vegf-therapies-in-retinal-vascular-diseases</loc><video:video><video:publication_date>2026-05-21</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/e6a90538ee7f7775d8579cc09a8401c630648abe-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[Current Role of Anti-VEGF Therapies in Retinal Vascular Diseases]]></video:title><video:description><![CDATA[How anti-VEGF injections reshape wet AMD, DME, and vein occlusion care, preserving vision—plus what real-world access barriers mean for patients.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6396070084112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/fixed-duration-av-is-a-compelling-option-with-important-caveats-adam-kittai-md</loc><video:video><video:publication_date>2026-05-21</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/49351261ba6f2ac5b9cd8f11659b0d389004a276-1200x640.png</video:thumbnail_loc><video:title><![CDATA[Fixed-Duration AV Is a Compelling Option, With Important Caveats: Adam Kittai, MD]]></video:title><video:description><![CDATA[Adam Kittai, MD, weighs the favorable safety profile of acalabrutinib plus venetoclax against lingering unknowns on long-term efficacy and high-risk patients.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6396068060112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/comparative-psa-risk-across-immunomodulatory-classes</loc><video:video><video:publication_date>2026-05-21</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/39fe3966526135f67acb59f508cb6afc3a2da701-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[Comparative PsA Risk Across Immunomodulatory Classes]]></video:title><video:description><![CDATA[A retrospective analysis comparing 3-year psoriatic arthritis incidence across immunomodulatory classes finds an emerging signal favoring IL-23 pathway agents—a finding with meaningful implications for treatment selection in patients at risk for joint disease.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6394093810112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/improving-coverage-and-multidisciplinary-care-delivery-for-mash</loc><video:video><video:publication_date>2026-05-20</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/cd00293b1376707a5d21a863360be3110ded9782-752x426.png</video:thumbnail_loc><video:title><![CDATA[Improving Coverage and Multidisciplinary Care Delivery for MASH]]></video:title><video:description><![CDATA[The panelist explored the following critical questions:

What systems-level strategies can improve coverage readiness for new metabolic dysfunction-associated steatohepatitis (MASH) treatments?

What system-wide transformations are necessary to sustain scalable, multidisciplinary MASH care?

What barriers exist to adopting emerging metabolic dysfunction-associated steatohepatitis (MASH) therapies at the system level, and how can they be overcome?

What clinical and economic evidence is needed for formulary adoption of new therapies?

The estimated financial burden of metabolic dysfunction-associated steatohepatitis (MASH) is considerable. How does delayed detection and intervention impact the overall cost of MASH care?

What financial and clinical benefits arise from implementing early detection programs for MASH?

How does fragmentation within the MASH ecosystem affect value-based care outcomes? 

How can population health efforts optimize these outcomes?
]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6396158389112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/system-level-barriers-and-evidence-gaps-in-the-adoption-of-emerging-mash-therapies</loc><video:video><video:publication_date>2026-05-20</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/cd00293b1376707a5d21a863360be3110ded9782-752x426.png</video:thumbnail_loc><video:title><![CDATA[System-Level Barriers and Evidence Gaps in the Adoption of Emerging MASH Therapies]]></video:title><video:description><![CDATA[In this episode, 'System-Level Barriers and Evidence Gaps in the Adoption of Emerging MASH Therapies,' the expert hepatologist explored the following questions:

What barriers exist to adopting emerging metabolic dysfunction-associated steatohepatitis (MASH) therapies at the system level, and how can they be overcome?

What clinical and economic evidence is needed for formulary adoption of new therapies?

The estimated financial burden of metabolic dysfunction-associated steatohepatitis (MASH) is considerable. How does delayed detection and intervention impact the overall cost of MASH care?

What financial and clinical benefits arise from implementing early detection programs for MASH?

How does fragmentation within the MASH ecosystem affect value-based care outcomes? 

How can population health efforts optimize these outcomes?
]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6396158578112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/the-financial-and-clinical-cost-of-delayed-mash-detection-and-fragmented-care</loc><video:video><video:publication_date>2026-05-20</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/cd00293b1376707a5d21a863360be3110ded9782-752x426.png</video:thumbnail_loc><video:title><![CDATA[The Financial and Clinical Cost of Delayed MASH Detection and Fragmented Care]]></video:title><video:description><![CDATA[Welcome back to another AJMC Insights series. In this episode titled, 'The Financial and Clinical Cost of Delayed MASH Detection and Fragmented Care', Dr. Jaideep Behari led the conversation about the following questions:

The estimated financial burden of metabolic dysfunction-associated steatohepatitis (MASH) is considerable. How does delayed detection and intervention impact the overall cost of MASH care?

What financial and clinical benefits arise from implementing early detection programs for MASH?

How does fragmentation within the MASH ecosystem affect value-based care outcomes? 

How can population health efforts optimize these outcomes?
]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6396159461112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/rani-bansal-md-what-s-driving-rising-cancer-rates-in-young-women-and-are-we-screening-early-enough-</loc><video:video><video:publication_date>2026-05-20</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/65301d3d1b356866fd65c6eb533de51664e25705-1200x640.png</video:thumbnail_loc><video:title><![CDATA[Rani Bansal, MD: What's Driving Rising Cancer Rates in Young Women and Are We Screening Early Enough? ]]></video:title><video:description><![CDATA[Breast cancer incidence climbs in young women under 40 and risk-based screening earlier may help reduce this, explains Rani Bansai, MD.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6394689785112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/the-patient-voice-addressing-unmet-needs-and-access-in-alopecia-care</loc><video:video><video:publication_date>2026-05-20</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/0122f98f984368305638a39cae99e787ba414a0c-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[The Patient Voice: Addressing Unmet Needs and Access in Alopecia Care]]></video:title><video:description><![CDATA[After decades of painful alopecia treatments, a clinical-trial JAK inhibitor stops shedding fast and restores full hair—confidence included.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6394176104112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/sparsentan-approval-opens-new-era-in-fsgs-treatment-kirk-campbell-md</loc><video:video><video:publication_date>2026-05-19</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/b90afca67bcfda2e357c18fccf36b818f0ec5a42-1200x640.png</video:thumbnail_loc><video:title><![CDATA[Sparsentan Approval Opens New Era in FSGS Treatment: Kirk Campbell, MD]]></video:title><video:description><![CDATA[Kirk Campbell, MD, sees sparsentan as the beginning of a new treatment era for FSGS, a condition that has lacked approved therapies until now. ]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6395970006112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/tezepelumab-showed-broad-benefit-across-asthma-outcomes-michael-wechsler-md-mmsc</loc><video:video><video:publication_date>2026-05-19</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/42a62f3dc4eb591408c24f47f88feacc0fb45c6e-1200x640.png</video:thumbnail_loc><video:title><![CDATA[Tezepelumab Showed Broad Benefit Across Asthma Outcomes: Michael Wechsler, MD, MMSc]]></video:title><video:description><![CDATA[SUNRISE data showed tezepelumab improved asthma outcomes while reducing steroid dependence in severe asthma.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6395898545112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/community-oncology-s-biggest-battles-and-how-to-fight-back-diana-verrilli-ms</loc><video:video><video:publication_date>2026-05-19</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/6cbf94868a493807be69eb87b1d45dbdb39019d4-1200x640.png</video:thumbnail_loc><video:title><![CDATA[Community Oncology’s Biggest Battles, and How to Fight Back: Diana Verrilli, MS]]></video:title><video:description><![CDATA[Diana Verrilli, MS, of Navista breaks down the regulatory, payer, and cybersecurity pressures threatening community oncology practices—and maps a path forward.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6395961583112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/icu-learning-systems-could-transform-critical-care-chad-hochberg-md</loc><video:video><video:publication_date>2026-05-19</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/ab6f5584a52bf08ce89181ad2ab841277674db61-1200x640.png</video:thumbnail_loc><video:title><![CDATA[ICU Learning Systems Could Transform Critical Care: Chad Hochberg, MD]]></video:title><video:description><![CDATA[Chad Hochberg, MD, discussed how ICU learning health systems and predictive tools may improve critical care delivery.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6395913306112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/sunrise-data-support-steroid-reduction-in-severe-asthma-michael-wechsler-md-mmsc</loc><video:video><video:publication_date>2026-05-19</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/42a62f3dc4eb591408c24f47f88feacc0fb45c6e-1200x640.png</video:thumbnail_loc><video:title><![CDATA[SUNRISE Data Support Steroid Reduction in Severe Asthma: Michael Wechsler, MD, MMSc]]></video:title><video:description><![CDATA[SUNRISE trial data showed tezepelumab reduced oral steroid use while maintaining asthma control in severe asthma.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6395898640112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/from-silos-to-holistic-care-implementing-early-detection-in-crm-syndrome</loc><video:video><video:publication_date>2026-05-19</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/be8b1bafd1bf2bb88298041f73e6ae0b864060c7-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[From Silos to Holistic Care: Implementing Early Detection in CRM Syndrome]]></video:title><video:description><![CDATA[Rising urine albumin signals hidden kidney and heart risk; learn why earlier UACR/eGFR screening and new therapies can change CKD outcomes.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6394588339112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/opioid-use-reduced-ocular-surgery-anton-kolomeyer</loc><video:video><video:publication_date>2026-05-18</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/f5359b15363233d1079f000da61ce6755cabb679-1200x640.png</video:thumbnail_loc><video:title><![CDATA[Opioid Use Duration Should Be Reduced After Ocular Surgery: Anton Kolomeyer, MD, PhD]]></video:title><video:description><![CDATA[Research done by Anton Kolomeyer, MD, PhD, showed increasing prescription of opioid medication after ocular surgery.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6395693639112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/passage-trial-shows-tezepelumab-benefit-in-diverse-asthma-groups-njira-l-lugogo-md-ms</loc><video:video><video:publication_date>2026-05-18</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/83d5bf09355fae9ca1608db13906448ebd26b58f-1200x640.png</video:thumbnail_loc><video:title><![CDATA[PASSAGE Trial Shows Tezepelumab Benefit in Diverse Asthma Groups: Njira L. Lugogo, MD, MS]]></video:title><video:description><![CDATA[PASSAGE trial data showed tezepelumab reduced asthma exacerbations in diverse and underrepresented patient populations, noted Njira L. Lugogo, MD.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6395896714112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/bleeding-risk-considerations-with-sotatercept-in-ctd-pah-rogerio-souza-md-phd</loc><video:video><video:publication_date>2026-05-18</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/c2103275eb5c3d2e7d79a8a157b364f9ef1bf072-1200x640.png</video:thumbnail_loc><video:title><![CDATA[Bleeding Risk Considerations With Sotatercept in CTD-PAH: Rogerio Souza, MD, PhD]]></video:title><video:description><![CDATA[ATS 2026 findings highlighted bleeding risks and hemodynamic responses with sotatercept in CTD-associated pulmonary arterial hypertension (PAH).]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6395894682112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/sotatercept-reduced-morbidity-in-ctd-pah-analysis-rogerio-souza-md-phd</loc><video:video><video:publication_date>2026-05-18</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/e50f1755d9dee2a5805e1f0ce8bb8afb10ee5fcd-1200x640.png</video:thumbnail_loc><video:title><![CDATA[Sotatercept Reduced Morbidity in CTD-PAH Analysis: Rogerio Souza, MD, PhD]]></video:title><video:description><![CDATA[null]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6395894853112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/recover-initiative-advances-long-covid-understanding-jerry-a-krishnan-md-phd</loc><video:video><video:publication_date>2026-05-18</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/0b8e46f59599b879185cf62bae97f4071ddf2cfd-1200x640.png</video:thumbnail_loc><video:title><![CDATA[RECOVER Initiative Advances Long COVID Understanding: Jerry A. Krishnan, MD, PhD]]></video:title><video:description><![CDATA[RECOVER Initiative findings highlighted the heterogeneity of long COVID symptoms and mechanisms in diverse patient populations.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6395899361112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/passage-study-expands-tezepelumab-data-in-severe-asthma-njira-l-lugogo-md</loc><video:video><video:publication_date>2026-05-18</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/db2e91ecd9f0de06fc950680d61ded6f252dcb63-1200x640.png</video:thumbnail_loc><video:title><![CDATA[PASSAGE Study Expands Tezepelumab Data in Severe Asthma: Njira L. Lugogo, MD, MS]]></video:title><video:description><![CDATA[PASSAGE study data showed tezepelumab improved asthma outcomes across diverse, underrepresented patient populations.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6395896715112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/community-bispecifics-success-hinges-on-education-reimbursement</loc><video:video><video:publication_date>2026-05-17</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/272db9462a43e1fb3ed05b40786e9c7b784103e8-1200x640.png</video:thumbnail_loc><video:title><![CDATA[Community Bispecifics Success Hinges on Education, Reimbursement]]></video:title><video:description><![CDATA[Community oncology can navigate bispecific therapy rollout with staff training, clear handoffs, and reliable reimbursement, said Lekan Ajayi, PharmD.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6395563637112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/bispecifics-step-up-dosing-pressure-community-resources</loc><video:video><video:publication_date>2026-05-15</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/272db9462a43e1fb3ed05b40786e9c7b784103e8-1200x640.png</video:thumbnail_loc><video:title><![CDATA[Bispecifics' Step-Up Dosing Puts Pressure on Community Resources]]></video:title><video:description><![CDATA[Community oncology grapples with the logistics of bispecifics with step-up dosing straining staff and reimbursement, said Lekan Ajayi, PharmD.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6395562355112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/mrd-moves-to-center-stage-in-multiple-myeloma-nicholas-richardson-do-mph</loc><video:video><video:publication_date>2026-05-14</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/6c78d4d202df4ff6877ac5fcc203b2d98cd7cce6-1200x640.png</video:thumbnail_loc><video:title><![CDATA[MRD Moves to Center Stage in Multiple Myeloma: Nicholas Richardson, DO, MPH]]></video:title><video:description><![CDATA[Nicholas Richardson, DO, MPH, discussed the implications of the FDA’s January draft guidance proposing MRD-negative complete response as a primary end point for accelerated approval in multiple myeloma.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6395579428112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/burdensome-symptoms-and-psychological-well-being-in-psoriasis</loc><video:video><video:publication_date>2026-05-14</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/39fe3966526135f67acb59f508cb6afc3a2da701-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[Burdensome Symptoms and Psychological Well-Being in Psoriasis]]></video:title><video:description><![CDATA[An analysis of the POSITIVE study showed that tildrakizumab not only clears skin but substantially reduces itch, pain, and fatigue, with psychological well-being scores ultimately surpassing general population norms by year 2.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6394094094112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/the-first-all-oral-regimen-for-aml-is-a-game-changer-karilyn-larkin-md</loc><video:video><video:publication_date>2026-05-13</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/3ab2a089916e2c6ff8b26526e71e9e05ec1157f7-1200x640.png</video:thumbnail_loc><video:title><![CDATA[The First All-Oral Regimen for AML Is a Game Changer: Karilyn Larkin, MD]]></video:title><video:description><![CDATA[Karilyn Larkin, MD, weighs in on how decitabine/cedazuridine/venetoclax could transform the AML treatment experience—and the new responsibilities it places on patients.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6395452811112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/clinical-trial-education-treatment-access-central-to-improving-lung-cancer-care-deborah-doroshow-md-phd</loc><video:video><video:publication_date>2026-05-13</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/e1f7294b7b0c904d43f59cc627f9829d9acd014f-1200x640.png</video:thumbnail_loc><video:title><![CDATA[Clinical Trial Education, Treatment Access Central to Improving Lung Cancer Care: Deborah Doroshow, MD, PhD]]></video:title><video:description><![CDATA[Deborah Doroshow, MD, PhD, discusses lung cancer trial access, targeted therapy advances, and treatment gaps in part 2 of her interview.
]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6394969567112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/the-evolution-of-alopecia-treatment-from-steroid-injections-to-jak-inhibitors</loc><video:video><video:publication_date>2026-05-13</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/0122f98f984368305638a39cae99e787ba414a0c-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[The Evolution of Alopecia Treatment: From Steroid Injections to JAK Inhibitors]]></video:title><video:description><![CDATA[After decades of painful alopecia treatments, a JAK inhibitor trial stops shedding fast and restores full hair—confidence returns.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6394177201112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/covid-19-variants-and-immunocompromised-protection-strategies-muhammed-bilal-abid-md</loc><video:video><video:publication_date>2026-05-12</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/5210c05212d4866f6bb4bb1fcdad7458d01a7768-1200x640.png</video:thumbnail_loc><video:title><![CDATA[COVID-19 Variants and Immunocompromised Protection Strategies: Muhammad Bilal Abid, MD]]></video:title><video:description><![CDATA[Muhammad Bilal Abid, MD, discusses COVID-19 variant surveillance, monoclonal antibodies, and layered prevention in immunocompromised patients.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6394777838112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/highlighting-benefits-for-patients-can-help-maintain-adherence-for-retinal-treatments-anton-m-kolomeyer-md-phd</loc><video:video><video:publication_date>2026-05-12</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/f5359b15363233d1079f000da61ce6755cabb679-1200x640.png</video:thumbnail_loc><video:title><![CDATA[Highlighting Benefits for Patients Can Help Maintain Adherence for Retinal Treatments: Anton M. Kolomeyer, MD, PhD]]></video:title><video:description><![CDATA[Emphasizing the areas that can be improved when adherent to medication can be a means of keeping patients with retina diseases on their treatment, notes Anton M. Kolomeyer, MD, PhD.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6395264163112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/from-evidence-to-action-what-clinicians-can-do-to-transform-cholesterol-care</loc><video:video><video:publication_date>2026-05-12</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/cf9ce71c1f1cd31d9003a406535286464df9db3c-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[From Evidence to Action: What Clinicians Can Do to Transform Cholesterol Care]]></video:title><video:description><![CDATA[Across a landmark guideline update, a primary prevention trial, and the first treat-to-target proof of concept, the message is consistent: lower LDL for longer saves lives—and achieving that goal in practice demands goals, teams, tools, and lifestyle as the foundation.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6393574658112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/highlighting-treatment-gaps-the-potential-of-combination-therapy-in-cholesterol-management</loc><video:video><video:publication_date>2026-05-12</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/cf9ce71c1f1cd31d9003a406535286464df9db3c-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[Highlighting Treatment Gaps, the Potential of Combination Therapy in Cholesterol Management]]></video:title><video:description><![CDATA[Even with a treat-to-target protocol, only 61% of Ez-PAVE participants reached goal—but the trial's broader lesson is that combination therapy and equitable access to newer agents are the path to closing the gap.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6393572543112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/addressing-the-challenges-of-undiagnosed-chronic-kidney-disease</loc><video:video><video:publication_date>2026-05-12</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/be8b1bafd1bf2bb88298041f73e6ae0b864060c7-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[Addressing the Challenges of Undiagnosed Chronic Kidney Disease]]></video:title><video:description><![CDATA[Welcome back to another AJMC Insights series. In this episode titled, ‘Addressing the Challenges of Undiagnosed Chronic Kidney Disease’, Manisha Jhamb led the conversation]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6394587338112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/using-history-humanity-to-shape-cancer-care-conversations-deborah-doroshow-md-phd</loc><video:video><video:publication_date>2026-05-10</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/e1f7294b7b0c904d43f59cc627f9829d9acd014f-1200x640.png</video:thumbnail_loc><video:title><![CDATA[Using History, Humanity to Shape Cancer Care Conversations: Deborah Doroshow, MD, PhD]]></video:title><video:description><![CDATA[Deborah Doroshow, MD, PhD, blends oncology and history of medicine to guide cancer care, emphasizing communication, trust, and health equity.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6394885177112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/what-now-predicts-outcomes-in-older-adults-with-all-emily-k-curran-md</loc><video:video><video:publication_date>2026-05-07</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/c5d69fcf5d5618e471613b319e0440fd0f0cee7a-1200x640.png</video:thumbnail_loc><video:title><![CDATA[What Now Predicts Outcomes in Older Adults With ALL: Emily K. Curran, MD]]></video:title><video:description><![CDATA[Once-feared disease markers are losing their sting as targeted therapies reshape the landscape of ALL, Emily K. Curran, MD, told AJMC.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6394877098112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/breaking-down-frontline-btk-inhibitor-selection-in-cll-kerry-rogers-md</loc><video:video><video:publication_date>2026-05-07</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/127f2dcd308907341a216c7d6bd91ca3605bf48f-1200x640.png</video:thumbnail_loc><video:title><![CDATA[Breaking Down Frontline BTK Inhibitor Selection in CLL: Kerry Rogers, MD]]></video:title><video:description><![CDATA[For BTK inhibitor selection in frontline CLL treatment, age, risk profile, and long-term sequencing strategy influence treatment decisions, says Kerry Rogers, MD.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6394827679112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/policy-reform-preventive-care-incentives-could-reshape-pediatric-medicaid-care-chris-johnson-mba</loc><video:video><video:publication_date>2026-05-07</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/186b5049a053c4b5a8ecc3e8da7e7d9a66266d1b-1472x808.png</video:thumbnail_loc><video:title><![CDATA[Policy Reform, Preventive Care Incentives Could Reshape Pediatric Medicaid Care: Chris Johnson, MBA]]></video:title><video:description><![CDATA[Chris Johnson, MBA, discusses how Medicaid incentives and higher primary-care pay can boost preventive pediatric care.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6394598540112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/skin-clearance-and-high-impact-area-response-in-the-positive-study</loc><video:video><video:publication_date>2026-05-07</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/39fe3966526135f67acb59f508cb6afc3a2da701-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[Skin Clearance and High-Impact Area Response in the POSITIVE Study]]></video:title><video:description><![CDATA[The POSITIVE study's 2-year real-world data confirm that tildrakizumab drives near-total skin clearance and sustained improvement in difficult-to-treat areas, lending important practical validity to the phase 3 trial results.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6394093811112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/turning-oncology-frustrations-into-quality-improvement-solutions-eileen-ehret-bs</loc><video:video><video:publication_date>2026-05-06</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/c18e87fe0aa2e6ba049606b7825c572c2269cdb7-1200x640.png</video:thumbnail_loc><video:title><![CDATA[Turning Oncology Frustrations Into Quality Improvement Solutions: Eileen Ehret, BS]]></video:title><video:description><![CDATA[Eileen Ehret, BS, Navista, focuses on aligning quality improvement with patient safety, engaging all stakeholders, and creating safe spaces to drive change in oncology.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6394788023112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/breaches-in-cybersecurity-could-disrupt-affect-patient-care-tarun-sondhi</loc><video:video><video:publication_date>2026-05-06</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/384ffa83280e776c90ce04da6855bf53110df58e-1280x720.jpg</video:thumbnail_loc><video:title><![CDATA[Breaches in Cybersecurity Could Disrupt, Affect Patient Care: Tarun Sondhi]]></video:title><video:description><![CDATA[Cyberattacks could disrupt or delay patient care, making cybersecurity important to protecting patients in health care.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6394685080112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/reclaiming-confidence-overcoming-the-emotional-and-social-toll-of-alopecia</loc><video:video><video:publication_date>2026-05-06</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/0122f98f984368305638a39cae99e787ba414a0c-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[Reclaiming Confidence: Overcoming the Emotional and Social Toll of Alopecia]]></video:title><video:description><![CDATA[Diagnosed with alopecia at 18 months, she navigates patchy hair loss, rural care gaps, and secrecy—until new treatments spark confidence.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6394177202112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/the-role-of-school-nurses-in-early-diabetes-detection-shara-bialo-md</loc><video:video><video:publication_date>2026-05-05</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/8d627261d954d0bcd4a8ca66e9162b3101137a59-1200x640.png</video:thumbnail_loc><video:title><![CDATA[The Role of School Nurses in Early Diabetes Detection: Shara Bialo, MD]]></video:title><video:description><![CDATA[Shara Bialo, MD, emphasizes the crucial role of school nurses in early detection of type 1 diabetes. ]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6394685501112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/hayley-knollman-md-highlights-growing-role-of-patient-preferences-in-breast-cancer-care</loc><video:video><video:publication_date>2026-05-05</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/0e2fd4d273db1cf4167694eec2b41d8c288d35f8-1171x654.png</video:thumbnail_loc><video:title><![CDATA[Hayley Knollman, MD, Highlights Growing Role of Patient Preferences in Breast Cancer Care]]></video:title><video:description><![CDATA[Shared decision-making and quality of life are increasingly shaping metastatic breast cancer care amid persistent social barriers, notes Hayley Knollman, MD.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6394606421112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/adapt-oculus-trial-shows-promising-results-in-treatment-efficacy-for-ocular-mg-carolina-barnett-tapia-md-phd</loc><video:video><video:publication_date>2026-05-05</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/95d5f87bc27f30ed0e573f64774801af31daebf9-1280x720.jpg</video:thumbnail_loc><video:title><![CDATA[ADAPT OCULUS Trial Shows Promising Results in Treatment Efficacy for Ocular MG: Carolina Barnett-Tapia, MD, PhD]]></video:title><video:description><![CDATA[Carolina Barnett-Tapia, MD, PhD, discusses the results of the ADAPT OCULUS trial, which found promising results for treating patients with ocular myasthenia gravis.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6394602689112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/ez-pave-lower-cholesterol-target-outperforms-historic-target-in-ascvd</loc><video:video><video:publication_date>2026-05-05</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/cf9ce71c1f1cd31d9003a406535286464df9db3c-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[Ez-PAVE: Lower Cholesterol Target Outperforms Historic Target in ASCVD]]></video:title><video:description><![CDATA[Ez-PAVE delivers the first direct trial evidence that targeting LDL below 55 mg/dL is superior to below 70 mg/dL in ASCVD patients—providing proof of concept for treat-to-target strategies and a wake-up call about clinical inertia.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6393573151112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/whats-next-for-systemic-therapy-in-cscc</loc><video:video><video:publication_date>2026-05-05</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/88a8eef0d85d435b85b5ed0c5f92696000288dc8-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[What’s Next for Systemic Therapy in CSCC?]]></video:title><video:description><![CDATA[Systemic therapy for CSCC is evolving toward earlier use, combination and de-escalation strategies, and biomarker-driven personalization to improve outcomes and reduce toxicity.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6391139875112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/the-future-of-long-acting-therapies-in-reaching-unsuppressed-patients</loc><video:video><video:publication_date>2026-05-05</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/2145d00c47be064dd047d335bcbaf96078efda2f-776x438.png</video:thumbnail_loc><video:title><![CDATA[The Future of Long-Acting Therapies in Reaching Unsuppressed Patients]]></video:title><video:description><![CDATA[Long-acting therapies could be key to engaging unsuppressed patients and closing persistent gaps in HIV care.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6392177867112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/earlier-intervention-lasting-benefit-what-vesalius-cv-tells-us-about-timing-and-future-guidelines</loc><video:video><video:publication_date>2026-05-05</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/cf9ce71c1f1cd31d9003a406535286464df9db3c-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[Earlier Intervention, Lasting Benefit: What VESALIUS-CV Tells Us About Timing and Future Guidelines]]></video:title><video:description><![CDATA[Landmark analyses from VESALIUS-CV reveal that the cardiovascular benefits of intensive LDL lowering build meaningfully over time in primary prevention—reinforcing the "lower for longer" principle and pointing toward lower LDL targets for high-risk diabetic patients.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6393575166112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/the-societal-impact-of-stroke-prevalence-pathophysiology-and-economic-burden</loc><video:video><video:publication_date>2026-05-04</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/a9b3baf08720deefc3c23a79543e627a81469809-3456x1920.png</video:thumbnail_loc><video:title><![CDATA[The Societal Impact of Stroke: Prevalence, Pathophysiology, and Economic Burden]]></video:title><video:description><![CDATA[Panelists examine the societal impact of stroke by outlining its prevalence, underlying pathophysiology, key modifiable risk factors, and the substantial clinical, economic, and long-term disability burden it places on patients and the healthcare system.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6394599629112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/foundations-of-stroke-care-understanding-classification-and-clinical-presentation</loc><video:video><video:publication_date>2026-05-04</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/a9b3baf08720deefc3c23a79543e627a81469809-3456x1920.png</video:thumbnail_loc><video:title><![CDATA[Foundations of Stroke Care: Understanding Classification and Clinical Presentation]]></video:title><video:description><![CDATA[Panelists explore stroke classification and clinical presentation, highlighting key differences between ischemic and hemorrhagic strokes, the TOAST system for subtype identification, and the importance of understanding underlying causes to guide diagnosis and long-term management.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6394599630112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/the-future-of-medicaid-pediatric-care-and-value-based-partnerships-chris-johnson-mba</loc><video:video><video:publication_date>2026-04-30</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/186b5049a053c4b5a8ecc3e8da7e7d9a66266d1b-1472x808.png</video:thumbnail_loc><video:title><![CDATA[The Future of Medicaid Pediatric Care and Value-Based Partnerships: Chris Johnson, MBA]]></video:title><video:description><![CDATA[Chris Johnson, MBA, explains how retail-based pediatric clinics and smart tech can expand Medicaid access and streamline visits.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6394088899112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/patient-centered-oncology-care-guidelines-and-expertise-drive-value-in-practice-seungjean-chai-md</loc><video:video><video:publication_date>2026-04-30</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/b66b7894f7e8de3e2938c8eec38b05717f6d6f29-1200x640.png</video:thumbnail_loc><video:title><![CDATA[Patient-Centered Oncology Care, Guidelines, and Expertise Drive Value in Practice: Seungjean Chai, MD]]></video:title><video:description><![CDATA[At the IVBM Charlotte event, Seungjean Chai, MD, emphasized that patient-centered design, guidelines, and subspecialty expertise are essential to high-value oncology care.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6394253698112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/the-journey-of-living-with-alopecia-overcoming-early-barriers-to-care</loc><video:video><video:publication_date>2026-04-30</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/0122f98f984368305638a39cae99e787ba414a0c-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[The Journey of Living With Alopecia: Overcoming Early Barriers to Care ]]></video:title><video:description><![CDATA[Diagnosed with childhood alopecia, she navigates patchy hair loss, limited rural care, stigma, and uncertainty—until treatments help her share her story.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6394175715112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/unmet-needs-and-efficacy-benchmarks-in-nail-psoriasis</loc><video:video><video:publication_date>2026-04-30</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/39fe3966526135f67acb59f508cb6afc3a2da701-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[Unmet Needs and Efficacy Benchmarks in Nail Psoriasis]]></video:title><video:description><![CDATA[A phase 3b trial demonstrates that tildrakizumab meets robust efficacy endpoints for nail psoriasis—an historically difficult manifestation to treat—while maintaining a favorable long-term safety profile through week 72.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6394092638112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/operationalizing-bite-therapies-in-community-oncology-kaitlyn-schomberg-pharmd</loc><video:video><video:publication_date>2026-04-29</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/acef3711540d172cc2bd736681d103c04245543c-1200x640.png</video:thumbnail_loc><video:title><![CDATA[Operationalizing BiTE Therapies in Community Oncology: Kaitlyn Schomberg, PharmD]]></video:title><video:description><![CDATA[Kaitlyn Schomberg, PharmD, discusses BiTE therapy adoption, toxicity management, and care coordination in community oncology settings.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6394181318112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/payment-models-taking-shape-for-advanced-therapies-fran-gregory-pharmd</loc><video:video><video:publication_date>2026-04-29</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/4ab58a5258df8f993bf406cbaafb93288b153ad2-1200x640.jpg</video:thumbnail_loc><video:title><![CDATA[Payment Models Taking Shape for Advanced Therapies: Fran Gregory, PharmD]]></video:title><video:description><![CDATA[Advanced therapies are pressuring reimbursement and necessitating real-world durability data and new payment models, said Fran Gregory, PharmD.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6394189942112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/the-pharmacist-as-the-cll-communication-hub-karen-fancher-pharmd-bcop</loc><video:video><video:publication_date>2026-04-29</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/db642b0610b9f14e444020d2b239efdd62a96fe9-1200x640.png</video:thumbnail_loc><video:title><![CDATA[The Pharmacist as the CLL Communication Hub: Karen Fancher, PharmD, BCOP]]></video:title><video:description><![CDATA[Karen Fancher, PharmD, BCOP, emphasizes a pharmacist’s pivotal role in CLL care through communication, adherence strategies, and bridging patients with medical teams.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6394212954112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/access-automation-and-what-works-in-pharmacy-ryan-telford-pharmd</loc><video:video><video:publication_date>2026-04-29</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/38f68c816ff78b9e8aac591f83da4d2e436a673e-1200x640.jpg</video:thumbnail_loc><video:title><![CDATA[Access, Automation, and What Works in Pharmacy: Ryan Telford, PharmD]]></video:title><video:description><![CDATA[Pharmacy innovation—from automation to cell and gene therapy—has moved from future promise to present reality, says Cencora's Ryan Telford, PharmD.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6394177004112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/amplify-the-patient-voice-in-community-oncology-care-rose-gerber-ms</loc><video:video><video:publication_date>2026-04-29</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/b6972ec221a2d421b35c18ea297657f328e0fb8d-1200x640.png</video:thumbnail_loc><video:title><![CDATA[Amplify the Patient Voice in Community Oncology Care: Rose Gerber, MS]]></video:title><video:description><![CDATA[Rose Gerber, MS, explains how listening, personal experience, and small steps can transform patients into powerful advocates for their own care.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6394182185112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/remote-therapy-monitoring-could-be-community-oncology-s-secret-weapon-lekan-ajayi-pharmd</loc><video:video><video:publication_date>2026-04-29</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/272db9462a43e1fb3ed05b40786e9c7b784103e8-1200x640.png</video:thumbnail_loc><video:title><![CDATA[Remote Therapy Monitoring Could Be Community Oncology’s Secret Weapon: Lekan Ajayi, PharmD]]></video:title><video:description><![CDATA[Lekan Ajayi, PharmD, explains how remote therapy monitoring keeps patients with cancer on track with their care and reduces emergency visits.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6394137129112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/new-data-prove-community-cancer-care-delivers-diana-verrilli-ms</loc><video:video><video:publication_date>2026-04-29</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/6cbf94868a493807be69eb87b1d45dbdb39019d4-1200x640.png</video:thumbnail_loc><video:title><![CDATA[New Data Prove Community Cancer Care Delivers: Diana Verrilli, MS]]></video:title><video:description><![CDATA[New research incorporating Flatiron Health and SEER data, confirms community oncology care matches or beats other settings, says Diana Verrilli, MS, Navista.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6394128739112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/doravirine-islatravir-maintains-viral-suppression-in-phase-3-hiv-trials-princy-kumar-md</loc><video:video><video:publication_date>2026-04-28</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/570baaaeac2d1f04d9e3830b8108ae922d8a17c2-1272x713.png</video:thumbnail_loc><video:title><![CDATA[DOR/ISL Maintains Viral Suppression in Phase 3 HIV Trials: Princy Kumar, MD]]></video:title><video:description><![CDATA[Newly FDA-approved doravirine/Islatravir maintained HIV suppression in phase 3 trials with comparable safety and minimal metabolic effects.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6394100883112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/multiple-myeloma-sequencing-evolves-with-car-t-mrd-insights-sylvester-homsy-md</loc><video:video><video:publication_date>2026-04-28</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/acb7a01625fb24e18ea32643fa1d4bf85bcb10cd-1200x640.png</video:thumbnail_loc><video:title><![CDATA[Multiple Myeloma Sequencing Evolves With CAR T, MRD Insights: Sylvester Homsy, MD]]></video:title><video:description><![CDATA[CAR-T and bispecifics in multiple myeloma are reshaping sequencing, enabling earlier use, but access and standardization challenges remain, per Sylvester Homsy, MD.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6394097634112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/us-pricing-reform-reshapes-drug-launch-strategies-dee-chaudhary</loc><video:video><video:publication_date>2026-04-28</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/6d02ffcd6162e3a56581da18e04589a83a225095-1200x640.jpg</video:thumbnail_loc><video:title><![CDATA[US Pricing Reform Reshapes Drug Launch Strategies: Dee Chaudhary]]></video:title><video:description><![CDATA[As pricing reforms like Most Favored Nation reshape global drug launches, patients may ultimately pay the highest price, said Dee Chaudhary of Clarivate.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6394103960112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/how-price-transparency-could-fix-the-abandoned-rx-issue-laura-jensen</loc><video:video><video:publication_date>2026-04-28</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/563850b53eafc77f61ce6b922e4746c1642d0fbb-1200x640.jpg</video:thumbnail_loc><video:title><![CDATA[How Price Transparency Could Fix the Abandoned Rx Issue: Laura Jensen]]></video:title><video:description><![CDATA[Drug pricing transparency and easy discounts cut abandoned prescriptions, as federal policies put pressure on pharma, says Laura Jensen of GoodRx.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6394102310112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/cutting-cancer-care-costs-rethinking-aca-policy-justin-favaro-md</loc><video:video><video:publication_date>2026-04-28</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/a093bc1d72b225fb4d54954eec6e8beec4ff2424-1200x640.png</video:thumbnail_loc><video:title><![CDATA[Cutting Cancer Care Costs, Rethinking ACA Policy: Justin Favaro, MD]]></video:title><video:description><![CDATA[Justin Favaro, MD, discusses independent oncology models, ACA challenges, and strategies to reduce health care costs at IVBM Charlotte 2026.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6394096942112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/why-coordinated-care-is-critical-in-advanced-cscc</loc><video:video><video:publication_date>2026-04-28</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/88a8eef0d85d435b85b5ed0c5f92696000288dc8-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[Why Coordinated Care Is Critical in Advanced CSCC]]></video:title><video:description><![CDATA[Multidisciplinary collaboration is essential in managing high-risk CSCC, helping clinicians overcome logistical barriers to deliver coordinated, individualized care.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6391137991112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/vesalius-cv-making-the-case-for-pcsk9-inhibition-before-atherosclerosis</loc><video:video><video:publication_date>2026-04-28</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/cf9ce71c1f1cd31d9003a406535286464df9db3c-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[VESALIUS-CV: Making the Case for PCSK9 Inhibition Before Atherosclerosis]]></video:title><video:description><![CDATA[VESALIUS-CV shows that evolocumab delivers a 31% relative risk reduction in major cardiovascular events in high-risk diabetic patients without established atherosclerosis—making a compelling case for intensive LDL lowering well before a first event.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6393573451112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/risk-enhancers-calcium-scoring-and-the-full-picture-of-cardiovascular-prevention</loc><video:video><video:publication_date>2026-04-28</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/cf9ce71c1f1cd31d9003a406535286464df9db3c-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[Risk Enhancers, Calcium Scoring, and the Full Picture of Cardiovascular Prevention]]></video:title><video:description><![CDATA[Beyond standard risk scores, the guideline highlights key risk enhancers—including lipoprotein(a), inflammation markers, and women's health factors—and elevates coronary artery calcium scoring as a Class I tool for resolving uncertainty in primary prevention.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6393573565112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/what-real-world-use-reveals-about-long-acting-therapy</loc><video:video><video:publication_date>2026-04-28</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/2145d00c47be064dd047d335bcbaf96078efda2f-776x438.png</video:thumbnail_loc><video:title><![CDATA[What Real-World Use Reveals About Long-Acting Therapy]]></video:title><video:description><![CDATA[Long-acting CAB+RPV may maintain efficacy even with delayed injections, offering real-world flexibility.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6392180011112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/neoadjuvant-immunotherapy-expands-options-in-complex-cscc</loc><video:video><video:publication_date>2026-04-28</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/88a8eef0d85d435b85b5ed0c5f92696000288dc8-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[Neoadjuvant Immunotherapy Expands Options in Complex CSCC]]></video:title><video:description><![CDATA[Neoadjuvant immunotherapy is expanding treatment options in CSCC by shrinking complex tumors, improving surgical outcomes, and potentially enhancing long-term disease control.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6391140733112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/community-oncology-is-fighting-back-and-winning-nicolas-ferreyros</loc><video:video><video:publication_date>2026-04-27</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/0b7a3e29573928cbb830f2a5433037cb27201c3d-1200x640.png</video:thumbnail_loc><video:title><![CDATA[Community Oncology Is Fighting Back, and Winning: Nicolas Ferreyros]]></video:title><video:description><![CDATA[Community oncology delivers top-tier cancer care close to home, said Nicolas Ferreyros, COA, championing research, advocacy, and innovation to prove it.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6393934863112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/innovation-and-collaboration-drive-community-oncology-forward-christine-pfaff-rph-mba</loc><video:video><video:publication_date>2026-04-27</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/fd44e3b22d92715b592bf4317c2971bda5f788be-1200x640.png</video:thumbnail_loc><video:title><![CDATA[Innovation and Collaboration Drive Community Oncology Forward: Christine Pfaff, RPh, MBA]]></video:title><video:description><![CDATA[COA’s Christine Pfaff, RPh, MBA, highlights clinical and operational innovation, AI adoption, and practice-sharing as keys to advancing community oncology care.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6393957458112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/innovation-ai-and-the-fight-to-stay-independent-johnetta-blakely-md-ms-mmhc</loc><video:video><video:publication_date>2026-04-27</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/ff3227d08f1c91ba484fedaf58e761c6af3fe4c3-1200x640.png</video:thumbnail_loc><video:title><![CDATA[Innovation, AI, and the Fight to Stay Independent: Johnetta Blakely, MD, MS, MMHC]]></video:title><video:description><![CDATA[COA's annual conference hits Orlando April 28, focusing on AI, targeted therapy innovation, and state-level oncology advocacy, explains cochair Johnetta Blakely, MD, MS, MMHC.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6393814467112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/inhaled-treprostinil-improves-fvc-in-ipf-phase-3-trial-steven-d-nathan-md</loc><video:video><video:publication_date>2026-04-24</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/a784d1b6bdcf2bf61cf7d4624ebf5674f1eae713-1200x640.png</video:thumbnail_loc><video:title><![CDATA[Inhaled Treprostinil Improves FVC in IPF Phase 3 Trial: Steven D. Nathan, MD]]></video:title><video:description><![CDATA[Phase 3 TETON-1 trial shows inhaled treprostinil improves FVC in IPF, signaling a potential new antifibrotic option.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6393501704112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/bispecific-antibodies-are-reshaping-multiple-myeloma-care-prerna-mewawalla-md</loc><video:video><video:publication_date>2026-04-24</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/e85211dad79c04188cf0a9eea038aae7be4cdc90-1200x675.jpg</video:thumbnail_loc><video:title><![CDATA[Bispecific Antibodies Are Reshaping Multiple Myeloma Care: Prerna Mewawalla, MD]]></video:title><video:description><![CDATA[Bispecific antibodies are delivering unprecedented response rates in multiple myeloma, offering fast, flexible options alongside CAR T-cell therapy, explains Prerna Mewawalla, MD.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6393575383112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/pediatric-care-deserts-and-emergency-room-reliance-chris-johnson-mba</loc><video:video><video:publication_date>2026-04-24</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/186b5049a053c4b5a8ecc3e8da7e7d9a66266d1b-1472x808.png</video:thumbnail_loc><video:title><![CDATA[Closing the Pediatric Care Gap Through Primary Care Reimbursement Reform: Chris Johnson, MBA]]></video:title><video:description><![CDATA[Pediatric care deserts push Medicaid families into costly ED visits; learn how primary care access gaps fuel chronic issues and spending.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6393733160112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/specialty-pharmacy-s-critical-role-as-advanced-therapies-move-into-the-community-fran-gregory-pharmd-mba</loc><video:video><video:publication_date>2026-04-23</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/1232a9adc9f3195dd0b6bbecf0f4a681f9e13033-2771x1439.png</video:thumbnail_loc><video:title><![CDATA[Specialty Pharmacy's Critical Role as Advanced Therapies Move Into the Community: Fran Gregory, PharmD, MBA]]></video:title><video:description><![CDATA[Fran Gregory, PharmD, MBA, explains why community providers can't go it alone—and how specialty pharmacy is stepping in to carry the load. ]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6393735939112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/access-timing-workflow-challenges-shape-biomarker-testing-in-nsclc-parth-desai-mbbs-md</loc><video:video><video:publication_date>2026-04-23</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/5bc49e7606f10be50c9a40477ce24dfe12022dec-1245x696.png</video:thumbnail_loc><video:title><![CDATA[Access, Timing, Workflow Challenges Shape Biomarker Testing in NSCLC: Parth Desai, MBBS, MD]]></video:title><video:description><![CDATA[Parth Desai, MBBS, MD, discusses how clinicians balance liquid biopsy, tissue testing, and fast-start chemo to personalize non–small cell lung cancer treatment.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6393501013112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/cemdisiran-safe-to-take-has-low-treatment-burden-in-gmg-tuan-vu-md</loc><video:video><video:publication_date>2026-04-23</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/88b997b0a027b4504d493eb7acbb7726e760e48c-1280x720.jpg</video:thumbnail_loc><video:title><![CDATA[Cemdisiran Safe to Take, Has Low Treatment Burden in gMG: Tuan Vu, MD]]></video:title><video:description><![CDATA[Cemdisiran offers lower treatment burden for patients living with generalized myasthenia gravis, only needing to be taken every 3 months.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6393306050112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/amcp-2026-highlights-managed-care-trends-in-oncology-policy-and-innovation</loc><video:video><video:publication_date>2026-04-23</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/cfad761b066e64488506ddaf32e2c91a14da7d13-352x143.png</video:thumbnail_loc><video:title><![CDATA[AMCP 2026 Highlights: Managed Care Trends in Oncology, Policy, and Innovation]]></video:title><video:description><![CDATA[AMCP 2026 spotlighted oncology innovation, AI, and payer strategies, with KOL insights on cost, access, and evolving managed care trends.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6393650329112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/expanding-the-toolkit-non-statin-therapies-broader-populations-and-closing-the-treatment-gap</loc><video:video><video:publication_date>2026-04-22</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/cf9ce71c1f1cd31d9003a406535286464df9db3c-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[Expanding the Toolkit: Non-Statin Therapies, Broader Populations, and Closing the Treatment Gap]]></video:title><video:description><![CDATA[For the first time, the 2026 ACC/AHA guideline provides strong, evidence-based recommendations for patients who cannot tolerate statins—a group historically underserved by prior guidance. Outcome data now support bempedoic acid (from the CLEAR trial), PCSK9 monoclonal antibodies, ezetimibe, and inclisiran as viable alternatives. Rather than defaulting to high-intensity statin doses, clinicians can consider combination strategies such as a moderate-intensity statin paired with ezetimibe—a pairing shown in the RACING trial to match the cardiovascular event reduction of high-intensity monotherapy while improving tolerability and LDL goal achievement. The "rule of sixes"—where doubling a statin dose yields only an additional 6% LDL reduction versus 18% from adding ezetimibe—further reinforces early combination thinking.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6393573046112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/starting-sooner-targeting-lower-how-updated-acc-aha-guidelines-redefine-lipid-lowering-strategy</loc><video:video><video:publication_date>2026-04-22</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/cf9ce71c1f1cd31d9003a406535286464df9db3c-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[Starting Sooner, Targeting Lower: How Updated ACC/AHA Guidelines Redefine Lipid-Lowering Strategy]]></video:title><video:description><![CDATA[The 2026 update to the ACC/AHA guideline for dyslipidemia management represents a meaningful shift in how and when clinicians should begin lipid-lowering therapy, Erin D. Michos, MD, MHS, professor of medicine, director of Women's Cardiovascular Health and associate director of Preventive Cardiology in the Division of Cardiology at Johns Hopkins University School of Medicine, explains. ]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6393573566112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/decentralized-trials-hold-promise-but-cost-infrastructure-challenges-remain-arturo-loaiza-bonilla-md</loc><video:video><video:publication_date>2026-04-21</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/2995dc687e6a306d6a5621623938143579d32635-1233x696.png</video:thumbnail_loc><video:title><![CDATA[Decentralized Trials Hold Promise, but Cost, Infrastructure Challenges Remain: Arturo Loaiza-Bonilla, MD]]></video:title><video:description><![CDATA[Clinical trials are evolving toward decentralized, patient-centered models, but enrollment challenges, outdated protocols, and infrastructure gaps persist.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6393484550112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/nimble-trial-shows-efficacy-of-cemdisiran-in-gmg-tuan-vu-md</loc><video:video><video:publication_date>2026-04-21</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/88b997b0a027b4504d493eb7acbb7726e760e48c-1280x720.jpg</video:thumbnail_loc><video:title><![CDATA[NIMBLE Trial Shows Efficacy of Cemdisiran in gMG: Tuan Vu, MD]]></video:title><video:description><![CDATA[Tuan Vu, MD, explains the results of the NIMBLE trial, whose results will be presented at the American Academy of Neurology conference.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6393300464112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/guideline-updates-reflect-growing-role-of-immunotherapy-in-cscc</loc><video:video><video:publication_date>2026-04-21</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/88a8eef0d85d435b85b5ed0c5f92696000288dc8-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[Guideline Updates Reflect Growing Role of Immunotherapy in CSCC]]></video:title><video:description><![CDATA[Immunotherapy—particularly PD-1 inhibition with cemiplimab—is reshaping CSCC care by expanding into neoadjuvant and adjuvant settings and offering durable disease control in high-risk patients.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6391139583112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/unmet-needs-and-key-takeaways-for-community-oncologists</loc><video:video><video:publication_date>2026-04-21</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/1f12cc94ed715aa6360bc6e5669713eee7a1506b-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[Unmet Needs and Key Takeaways for Community Oncologists]]></video:title><video:description><![CDATA[Chemotherapy sequencing in the ARPI era and the role of radiopharmaceuticals versus docetaxel remain unsettled, while genetics and PSMA-PET emerge as essential themes for community oncologists.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6392159179112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/the-future-of-psoriasis-management-integration-innovation-and-holistic-care</loc><video:video><video:publication_date>2026-04-21</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/d072e08706bc01a25795bad18219ae4adb16becc-778x438.png</video:thumbnail_loc><video:title><![CDATA[The Future of Psoriasis Management: Integration, Innovation, and Holistic Care]]></video:title><video:description><![CDATA[Benjamin Lockshin, MD, FAAD, offers a forward-looking synthesis of how psoriasis care has evolved toward holistic, personalized management—and where advances in oral therapies, biomarker-guided selection, and equitable access will define the next era of treatment.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6392168801112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/rethinking-when-to-start-long-acting-hiv-therapy</loc><video:video><video:publication_date>2026-04-21</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/2145d00c47be064dd047d335bcbaf96078efda2f-776x438.png</video:thumbnail_loc><video:title><![CDATA[Rethinking When to Start Long-Acting HIV Therapy]]></video:title><video:description><![CDATA[Real-world data suggest long-acting injectables may help achieve—not just maintain—viral suppression.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6392179222112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/psma-pet-and-the-evolving-imaging-landscape-in-prostate-cancer</loc><video:video><video:publication_date>2026-04-21</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/1f12cc94ed715aa6360bc6e5669713eee7a1506b-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[PSMA PET and the Evolving Imaging Landscape in Prostate Cancer]]></video:title><video:description><![CDATA[Radium-223 retains a role in osteoblastic bone-only disease, while PSMA PET has become indispensable across staging, recurrence detection, and patient selection for radioligand therapy.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6392160162112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/selecting-patients-for-immunotherapy-in-cscc-key-considerations</loc><video:video><video:publication_date>2026-04-21</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/88a8eef0d85d435b85b5ed0c5f92696000288dc8-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[Selecting Patients for Immunotherapy in CSCC: Key Considerations]]></video:title><video:description><![CDATA[Clinicians should consider systemic immunotherapy earlier in CSCC—especially in moderate- to high-risk cases—using a multidisciplinary, patient-centered approach to guide treatment decisions. ]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6391139094112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/addressing-family-caregiver-burden-in-breast-cancer-care-alyson-moadel-robblee-phd</loc><video:video><video:publication_date>2026-04-20</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/2843beae38cd20692ca6651f45643728046767eb-1974x1164.png</video:thumbnail_loc><video:title><![CDATA[Addressing Family Caregiver Burden in Breast Cancer Care: Alyson Moadel-Robblee, PhD]]></video:title><video:description><![CDATA[Alyson Moadel-Robblee, PhD, outlines how the BOLD Program proactively supports cancer caregivers through community-based care.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6392153050112</video:player_loc></video:video></url></urlset>